Ipca Laboratories Ltd share price logo

Ipca Laboratories Ltd (IPCALAB)


Get free price alerts. Set up your Free investment account to get Live Prices.
Q3 '23 Results
News and Events

Insights on Ipca Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    Promoter Holding Up


    Promoters have increased holdings from 46.29% to 46.30% in Mar 2024 quarter


    FII Holding Up


    Foreign Institutions have increased holdings from 10.27% to 10.51% in Mar 2024 quarter

  • imgNO EFFECT

    Against Peers


    In the last 1 year, Zydus Lifesciences Ltd has given 94.4% return, outperforming this stock by 41.7%

  • imgNO EFFECT

    Against Peers


    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 119.1% return, outperforming this stock by 107.1%


    Profit Down


    Netprofit is down for the last 2 quarters, 179.88 Cr → 59.59 Cr (in ₹), with an average decrease of 66.9% per quarter


    MF Holding Down


    Mutual Funds have decreased holdings from 29.25% to 28.83% in Mar 2024 quarter


    Price Dip


    In the last 7 days, IPCALAB stock has moved down by -4.7%


    Retail Holding Down


    Retail Investor have decreased holdings from 8.92% to 8.82% in Mar 2024 quarter


    Revenue Fall


    Revenue is down for the last 2 quarters, 2.14K Cr → 2.05K Cr (in ₹), with an average decrease of 4.3% per quarter


  • Day's Low

    Day's High

  • 52 Week's Low

    52 Week's High

1 Month Return-13.89 %
3 Month Return-4.15 %
1 Year Return+ 52.66 %
Previous Close₹1,125.45
Upper Circuit-
Lower Circuit-
Market Cap₹28,553.14Cr

Analyst Rating

based on 18 analysts


Based on 18 analysts offering long term price targets for Ipca Laboratories Ltd. An average target of ₹1196.94

Source: S&P Global Market Intelligence

Company Information

Ipca Laboratories is a fully integrated global pharmaceutical company, manufacturing and marketing over 350 formulations and 80 APIs in over 100 countries around the world. Established in 1949, with its original name as Indian Pharmaceutical Combine Association Limited, Ipca has 17 manufacturing units in India, producing APIs and Formulations that are approved by major drug regulatory authorities, including the US FDA, UK MHRA, South African MCC, Brazilian ANVISA and Australian TGA. Apart from native India, Ipca is also a recognized supplier of intermediates and APIs⁠—Atenolol, Chloroquine Phosphate, Furosemide, and Pyrantel Salts⁠—globally. Ipca has received accreditation from ISO 9001, Forbes Global 200 best small companies, WHOGMP, INVIMA Colombian, and German standards, making it a respected name in the pharmaceutical industry. Recently, Ipca has acquired a number of companies, namely Krebs Biochemicals and Industries Ltd., Pisgah Labs Inc., Trophic Wellness Private Ltd, Lyka Labs Limited, and M/s. Ramdev Chemical Private Limited, to further extend its presence in the global market.

Share Price: ₹1136.40 per share as on 21 Jun, 2024 04:01 PM
Market Capitalisation: ₹28,553.14Cr as of today
Revenue: ₹2,033.01Cr as on March 2024 (Q1 24)
Net Profit: ₹2.91Cr as on March 2024 (Q1 24)
Listing date: 03 Nov, 1994
Chairperson Name: Premchand Godha
OrganisationIpca Laboratories Ltd
E-voting on sharesClick here to vote

Key events for Ipca Laboratories Ltd

  • Ipca Labs Q4 FY24 Net Sales Up 34.49% YoY - 18 Jun, 2024

    Ipca Laboratories reported a 34.49% YoY increase in net sales for Q4 FY24, with EBITDA up by 56.75%. However, quarterly net profit decreased by 22.12% YoY and EPS decreased from Rs. 3.02 to Rs. 2.35. The stock has given returns of 6.97% over the last 6 months and 64.80% over the last 12 months.

  • Sharekhan Recommends Buying Ipca Laboratories Shares - 12 Jun, 2024

    Ipca Laboratories' Q4FY2024 performance exceeded expectations, with sales growing 43.6% YoY to Rs. 2,020 crore, EBITDA increasing 44.7% YoY to Rs. 321 crore, and APAT rising 110% YoY to Rs. 165 crore. Sharekhan recommends buying shares with a target price of Rs. 1350.

  • Ipca Laboratories Expected to Produce Higher Profit Next Year - 07 Jun, 2024

    Despite unusual expenses reducing the company's profit by ₹1.1b over the last year, Ipca Laboratories' EPS is up 16% in the past twelve months. Analysts expect a higher profit next year assuming no repeat of unusual expenses.

  • Prabhudas Lilladher Downgrades Rating on Ipca Laboratories - 04 Jun, 2024

    Prabhudas Lilladher has downgraded its rating on Ipca Laboratories from Hold to Reduce with a revised target price of Rs 1,150/share. The Q4 EBITDA was below their estimate and the management guidance for revenue growth was also lower than expected. Recovery in API segment and US sales is likely to be gradual. At CMP, the stock is trading at 30x PE and 16x EV/EBTIDA on FY26E.

  • Ipca Labs Stock Drops Despite Higher Revenue Guidance - 31 May, 2024

    Shares of IPCA Labs fell 8.23% despite projecting higher revenue guidance for FY25. Brokerages slashed their target price due to weak Q4 performance and reduced earnings estimates. Prabhudas Lilladher has a reduce call on the stock with a target price of Rs 1150.

  • IPCA Laboratories Reports Mixed Q4 Results - 30 May, 2024

    IPCA Laboratories reports mixed Q4 results with an increase in revenue but a decrease in profit compared to the same period last year. The market performance shows negative returns in the last week but positive returns over the last six months.

  • Ipca Labs Reports Decline in Q4FY24 Net Profit Despite Revenue Growth - 29 May, 2024

    Despite a 34.5% increase in revenue, IPCA Laboratories reported a 22% decline in Q4FY24 net profit. The company's standalone net sales for March 2024 were up 7.78% YoY. The stock saw a surge in trading volume on NSE.

  • Ipca Laboratories Ltd's High P/E Ratio Indicates Positive Future Growth - 24 May, 2024

    Despite growing earnings less than most other companies lately, Ipca Laboratories Ltd has a high P/E ratio of 58.8x as investors anticipate a marked improvement in its earnings performance. Analysts predict EPS to climb by 56% during the coming year, which is higher than the broader market forecast of 25%. Shareholders are holding on to their shares for a potentially prosperous future.

Ipca Laboratories Ltd Valuation

Ipca Laboratories Ltd in the last 5 years

  • Overview

  • Trends

Lowest (18.72x)

October 10, 2019

Today (52.15x)

June 20, 2024

Industry (64.02x)

June 20, 2024

Highest (62.66x)

April 18, 2024


Mutual Fund Holdings

Funds Holdings
HDFC Mid-Cap Opportunities Fund -Direct Plan - Growth OptionHDFC Mid-Cap Opportunities Fund -Direct Plan - Growth Option2.76%
Kotak Emerging Equity Scheme Direct GrowthKotak Emerging Equity Scheme Direct Growth2.06%
DSP Midcap Fund Direct Plan GrowthDSP Midcap Fund Direct Plan Growth3.37%
Parag Parikh Flexi Cap Direct GrowthParag Parikh Flexi Cap Direct Growth0.61%
Nippon India Growth Fund - Direct Plan - GrowthNippon India Growth Fund - Direct Plan - Growth1.28%

Shareholding Pattern

InvestorsHoldings %Prev. 1 periods3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Ipca Laboratories Ltd shares.

Ipca Laboratories Ltd (IPCALAB) share price today is ₹1136.4

Ipca Laboratories Ltd is listed on NSE

Ipca Laboratories Ltd is listed on BSE

  • Today’s highest price of Ipca Laboratories Ltd is ₹1143.8.
  • Today’s lowest price of Ipca Laboratories Ltd is ₹1124.05.

PE Ratio of Ipca Laboratories Ltd is 52.15

PE ratio = Ipca Laboratories Ltd Market price per share / Ipca Laboratories Ltd Earnings per share

Today’s traded volume of Ipca Laboratories Ltd(IPCALAB) is 8.00L.

Today’s market capitalisation of Ipca Laboratories Ltd(IPCALAB) is ₹28553.14Cr.

Ipca Laboratories Ltd(IPCALABPrice
52 Week High
52 Week Low

Ipca Laboratories Ltd(IPCALAB) share price is ₹1136.4. It is down -17.33% from its 52 Week High price of ₹1374.6

Ipca Laboratories Ltd(IPCALAB) share price is ₹1136.4. It is up 64.41% from its 52 Week Low price of ₹691.2

Ipca Laboratories Ltd(IPCALABReturns
1 Day Returns
1 Month Returns
3 Month Returns
1 Year Returns